文献速递浆细胞疾病

泊马度胺、地塞米松与达雷妥尤单抗治疗来那度胺治疗后复发难治多发性骨髓瘤

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
PubMed 文献 · Leukemia · 2020-05-06

MM-014 2期研究评估泊马度胺、低剂量地塞米松与达雷妥尤单抗用于经1-2线治疗后来那度胺预处理(75.0%来那度胺难治)的复发难治多发性骨髓瘤患者(N=112),总缓解率77.7%(来那度胺难治者76.2%),中位随访17.2个月,中位无进展生存期未达到,1年无进展生存率75.1%,常见3/4级血液学不良事件为中性粒细胞减少(62.5%)。

要点

  • 泊马度胺+地塞米松+达雷妥尤单抗在来那度胺预处理RRMM中总缓解率77.7%。
  • 来那度胺难治患者总缓解率76.2%,中位随访17.2个月时中位PFS未达到。
  • 3/4级中性粒细胞减少62.5%,3/4级感染31.3%,其中3/4级肺炎13.4%。

核心结论

  • 泊马度胺为基础的治疗在RRMM患者中最早可于二线使用,即使紧接来那度胺治疗失败后仍显示安全有效,提示无需换用免疫调节剂类别。

研究设计与样本

  • 2期MM-014研究纳入经1-2线既往治疗的来那度胺预处理复发难治多发性骨髓瘤患者,全部患者(N=112)最近一次既往方案均含来那度胺,其中75.0%为来那度胺难治。
  • 患者接受泊马度胺4 mg每日一次,第1-21天给药,地塞米松40 mg每周一次,28天为一周期;达雷妥尤单抗16 mg/kg按说明书给药。
  • 主要终点为总缓解率,次要终点包括无进展生存期和安全性。

主要发现

  • 总缓解率为77.7%,来那度胺难治患者为76.2%。
  • 中位随访17.2个月,中位无进展生存期未达到,1年无进展生存率75.1%。
  • 最常见的3/4级治疗中出现血液学不良事件为中性粒细胞减少,发生率62.5%。
  • 3/4级感染发生率为31.3%,其中3/4级肺炎为13.4%。

临床怎么用

  • 作者认为,泊马度胺为基础的治疗在RRMM患者中最早可于二线使用,即使紧接来那度胺治疗失败后仍安全有效,提示无需换用免疫调节剂类别。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The safety and efficacy of pomalidomide, low-dose dexamethasone, and daratumumab was evaluated in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM) after one to two prior treatment lines in the phase 2 MM-014 study. Patients received pomalidomide 4 mg daily from days 1-21 and dexamethasone 40 mg weekly (28-day cycles). Daratumumab 16 mg/kg was administered per label. Primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS) and safety. Per protocol, all patients (N = 112) had received lenalidomide in their most recent prior regimen (75.0% lenalidomide refractory). ORR was 77.7% (76.2% in lenalidomide-refractory patients); median follow-up was 17.2 months. Median PFS was not reached (1-year PFS rate 75.1%). The most common hematologic grade 3/4 treatment-emergent adverse event was neutropenia (62.5%). Grade 3/4 infections were reported in 31.3% of patients, including 13.4% with grade 3/4 pneumonia. These results demonstrate the safety and efficacy of pomalidomide-based therapy as early as second line in patients with RRMM, even immediately after lenalidomide failure, indicating that switching from the immunomodulatory agent class is not necessary.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Siegel DS, Schiller GJ, Samaras C, et al. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia. 2020. PMID: 32376855. doi:10.1038/s41375-020-0813-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。